A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2Bio--A2 Biotherapeutics, Inc., “A2 Bio”, is a biotechnology company focused on the development of a first-in-class Tmod™ T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells. A2 Bio today announced the...

Click to view original post